← Eichor
Condition: Non Metastatic Nasopharyngeal Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Non Metastatic Nasopharyngeal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06475300Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
NA · 1 location(s) · Zhongshan People's Hospital, Guangdong, China · NCT05994170Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Can
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT00900419Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05342792Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 · 2 location(s) · Shanghai Institute Of Biological Products · NCT06194656A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcin
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437522A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Phase 1 · 8 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05194982Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06516133A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 · 39 location(s) · SystImmune Inc. · NCT05983432PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NP
Phase 3 · 5 location(s) · Sun Yat-sen University · NCT07235319VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT06321939Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nas
Phase 3 · 1 location(s) · Ming-Yuan Chen · NCT07188584A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Naso
Phase 2 · 16 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05956587Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
Phase 3 · 5 location(s) · Sun Yat-sen University · NCT07661771
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.